{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:42Z","timestamp":1765546182031,"version":"3.37.3"},"reference-count":9,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Background: Prader-Willi syndrome (PWS), a neurologic disorder caused by a mutation of chromosome 15, is characterized by such symptoms as hypotonia, hypogonadism, hyperphagia, cognitive impairment, and difficult behaviors. One of the most concerning symptoms is hyperphagia, which can lead to uncontrolled obesity. Obesity is a major cause of increased morbidity and mortality in patients with PWS; however, diagnosing PWS early in life improves the prognosis.<\/jats:p>\n               <jats:p>Case Summary: An 11-year-old African American boy with a past medical history significant for PWS, attention deficit\/hyperactivity disorder, oppositional defiant disorder, obesity, and asthma was admitted after he became violent and destructive at his foster home while trying to get food. The patient had a 28-day stay on the children's crisis intervention unit where quetiapine was discontinued and he was maintained on clonidine 0.1 mg 3 times daily, hydroxyzine 25 mg in the morning and 50 mg at bedtime, montelukast 5 mg daily and titrated on methylphenidate 10 mg in the morning and 5 mg in the afternoon, topiramate 100 mg twice daily, and aripiprazole 10 mg twice daily. The patient displayed improved behavior control and less food-related aggression; he denied any side effects of medications.<\/jats:p>\n               <jats:p>Discussion: This case demonstrates the positive effects of topiramate for reducing aggression and demand for food in a child with PWS most likely due to an increase in satiety. It is hard to definitively attribute the positive response directly to topiramate. Further research should be conducted to determine if topiramate is an effective treatment option in these individuals.<\/jats:p>","DOI":"10.9740\/mhc.2017.01.007","type":"journal-article","created":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T19:05:44Z","timestamp":1483470344000},"page":"7-9","source":"Crossref","is-referenced-by-count":11,"title":["Topiramate in the treatment of Prader-Willi syndrome: A case report"],"prefix":"10.9740","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6038-9404","authenticated-orcid":false,"given":"Nicole","family":"East","sequence":"first","affiliation":[{"name":"(Corresponding author) Clinical Assistant Professor of Pharmacy Practice, Fairleigh Dickinson, University School of Pharmacy, Florham Park, New Jersey; Clinical Pharmacist\u2014Internal Medicine, Community Medical Center, Toms River, New Jersey, neast@fdu.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2718-6787","authenticated-orcid":false,"given":"Megan","family":"Maroney","sequence":"first","affiliation":[{"name":"Clinical Assistant Professor, Ernest Mario School of Pharmacy, Rutgers State University of New Jersey, New Brunswick, New Jersey; Clinical Psychiatric Pharmacist, Monmouth Medical Center, Long Branch, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"journal-title":"Chicago: The Association; c2004-15 [updated 2015; cited 2014 Dec 29]","article-title":"Medical Overview of PWS","author":"Prader-Willi Syndrome Association [Internet]","key":"2020060307302387600_i2168-9709-7-1-7-b01"},{"issue":"2","key":"2020060307302387600_i2168-9709-7-1-7-b02","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0887-8994(02)00490-3","article-title":"Topiramate effectiveness in Prader-Willi syndrome","volume":"28","author":"Smathers","year":"2003","journal-title":"Pediatr Neurol"},{"year":"2014","key":"2020060307302387600_i2168-9709-7-1-7-b03","article-title":"Topiramate [package insert]"},{"issue":"4","key":"2020060307302387600_i2168-9709-7-1-7-b04","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03340005","article-title":"Hyperphagia and self-mutilation in Prader-Willi syndrome: psychopharmacological issues","volume":"3","author":"Yaryura-Tobias","year":"1998","journal-title":"Eat Weight Disord"},{"issue":"3","key":"2020060307302387600_i2168-9709-7-1-7-b05","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00023210-200317030-00003","article-title":"Psychiatric disorders in Prader-Willi syndrome: epidemiology and management","volume":"17","author":"Dykens","year":"2003","journal-title":"CNS Drugs"},{"issue":"4","key":"2020060307302387600_i2168-9709-7-1-7-b06","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1352\/0895-8017(2004)109&lt;301:EOTIAW&gt;2.0.CO;2","article-title":"Effects of topiramate in adults with Prader-Willi syndrome","volume":"109","author":"Shapira","year":"2004","journal-title":"Am J Ment Retard"},{"issue":"2","key":"2020060307302387600_i2168-9709-7-1-7-b07","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1017\/S1461145702002833","article-title":"Topiramate attenuates self-injurious behaviour in Prader-Willi Syndrome","volume":"5","author":"Shapira","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"2020060307302387600_i2168-9709-7-1-7-b08","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00431-015-2670-x","article-title":"Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature","volume":"175","author":"Bonnot","year":"2016","journal-title":"Eur J Pediatr"},{"issue":"3","key":"2020060307302387600_i2168-9709-7-1-7-b09","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000108341","article-title":"Histamine and the regulation of body weight","volume":"86","author":"J\u00f8rgensen","year":"2007","journal-title":"Neuroendocrinology"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/1\/7\/2095437\/mhc_2017_01_007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/7\/1\/7\/2095437\/mhc_2017_01_007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:22:05Z","timestamp":1731687725000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/7\/1\/article-p7.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2017.01.007","relation":{},"ISSN":["2168-9709"],"issn-type":[{"type":"electronic","value":"2168-9709"}],"subject":[],"published":{"date-parts":[[2017,1,1]]}}}